Eton Pharmaceuticals Inc. (ETON) Misses Q2 EPS by 14c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of ($0.06), $0.14 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $7.4 million versus the consensus estimate of $9.5 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
• Greenlane Holdings Inc. (GNLN) reported Q2 result